Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

190 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Carboplatin plus weekly nanoparticle albumin-bound paclitaxel in elderly patients with previously untreated advanced squamous non-small-cell lung cancer selected based on Mini Nutritional Assessment short-form scores: a multicenter phase 2 study.
Shiroyama T, Tamiya M, Minami S, Takata S, Masuhiro K, Futami-Nishijima Y, Uenami T, Mori M, Koba T, Matsuki T, Takimoto T, Suzuki H, Okamoto N, Komuta K, Hirashima T, Kumanogoh A, Kijima T. Shiroyama T, et al. Cancer Chemother Pharmacol. 2017 Sep;80(3):461-467. doi: 10.1007/s00280-017-3385-7. Epub 2017 Jul 7. Cancer Chemother Pharmacol. 2017. PMID: 28688052 Clinical Trial.
Skin Rash Can Be a Useful Marker for Afatinib Efficacy.
Nasu S, Suzuki H, Shiroyama T, Tanaka A, Iwata K, Ryota N, Ueda Y, Takata SO, Masuhiro K, Morita S, Morishita N, Okamoto N, Hirashima T. Nasu S, et al. Among authors: shiroyama t. Anticancer Res. 2018 Mar;38(3):1783-1788. doi: 10.21873/anticanres.12416. Anticancer Res. 2018. PMID: 29491117
Transformation to small cell lung cancer after first-line afatinib treatment.
Shiroyama T, Nasu S, Tanaka A, Takata S, Masuhiro K, Takada H, Morita S, Morishita N, Suzuki H, Okamoto N, Kawahara K, Hirashima T. Shiroyama T, et al. Respir Med Case Rep. 2018 Mar 1;23:188-190. doi: 10.1016/j.rmcr.2018.02.011. eCollection 2018. Respir Med Case Rep. 2018. PMID: 29719814 Free PMC article.
Paradoxical response in a patient with non-small cell lung cancer who received nivolumab followed by anti-Mycobacterium tuberculosis agents.
Takata S, Koh G, Han Y, Yoshida H, Shiroyama T, Takada H, Masuhiro K, Nasu S, Morita S, Tanaka A, Hashimoto S, Uriu K, Suzuki H, Tamura Y, Okamoto N, Nagai T, Hirashima T. Takata S, et al. Among authors: shiroyama t. J Infect Chemother. 2019 Jan;25(1):54-58. doi: 10.1016/j.jiac.2018.06.016. Epub 2018 Jul 25. J Infect Chemother. 2019. PMID: 30055859 Free article.
190 results